ArticleJournal of clinical laboratory analysis2019
Effect of a functional variant of tumor necrosis factor-β gene in temporomandibular disorders: A pilot study.
Article in Journal of clinical laboratory analysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Analysis of Clinical, Biopsychosocial Factors and Mmp3 Polymorphism in Women with TMD.Diagnostics (Basel, Switzerland) · 2026Article
- The etiological effect and genetic risk of +252 A/G variant of TNF-β gene related to the susceptibility of urinary tract infection in a sample of Iraqi patients with type 2 diabetes: A case control study.Health science reports · 2023Article
- Genetic overlap between temporomandibular disorders and primary headaches: A systematic review.The Japanese dental science review · 2022Review
- Association of Estrogen Receptor 1 and Tumor Necrosis FactorDisease markers · 2020Article
- Effect of a functional variant of tumor necrosis factor-β gene in temporomandibular disorders: A pilot study.Journal of clinical laboratory analysis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTemporomandibular disorders (TMD) are a group of conditions that cause chronic orofacial pain. The tumor necrosis factor β (TNF-β) is a proinflammatory cytokine that is involved in the various aspects of the inflammatory process including organization and maintenance, and in the arrangement of cells at the inflammation site. The purpose of this study was to evaluate the correlation between TNF-β +252A/G (rs909253) variant and susceptibility to TMD in a Turkish cohort.
methodsThe study included 104 patients (26 males, 78 females) with TMD and 126 healthy controls (44 males, 82 females). The TNF-β +252A/G variant analysis was based on Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).
resultsThere was no deviation from HWA for TNF-β +252A/G variant in patient and control groups. There was significant difference in genotype and allele frequencies between patient group and control group in terms of TNF-β +252A/G variant, respectively (P = 0.010, 0.015). A significant increase in the TNF-β +252 AG genotype and G allele frequencies were observed in TMD patients compared to healthy controls. The individuals with GG genotype and G allele had an increased risk of developing TMD. A statistically significant association was observed when the patients were compared with the controls according to AA genotype vs AG+GG genotypes (P = 0.002, OR: 2.23, 95% CI:1.31-3.82). TNF-β +252A/G genotype distribution was associated with chewing problems (P = 0.046).
conclusionsIn conclusion, our results provided evidence that TNF-β +252A/G variant may contribute to TMD development in a Turkish cohort. Further studies are needed to confirm this observation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.